TriangleNCT02564198 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline to Date of Death from Any Cause (Up to 42 Months)
What was measured
Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.
Analysis population: All randomized participants who received at least one dose of study drug.
Groups in this outcome
8 mg/kg Ramucirumab (Part A)
Participants received 8 mg/kg Ramucirumab administered as an intravenous infusion Q2W with 3 doses per 42 day cycle.
12 mg/kg Ramucirumab (Part A)
Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.
12 mg/kg Ramucirumab (Part B)
Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.
| Group | Source count |
|---|---|
| 8 mg/kg Ramucirumab (Part A) | 8 |
| 12 mg/kg Ramucirumab (Part A) | 15 |
| 12 mg/kg Ramucirumab (Part B) | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 8 mg/kg Ramucirumab (Part A) | NA | Not reported | NA | NA | There were not enough events/deaths to compute a median or 95% confidence interval. |
| 12 mg/kg Ramucirumab (Part A) | NA | Not reported | NA | NA | There were not enough events/deaths to compute a median or 95% confidence interval. |
| 12 mg/kg Ramucirumab (Part B) | NA | Not reported | NA | NA | There were not enough events/deaths to compute a median or 95% confidence interval. |
Complete source fields
- classes
- categories
- measurements
- comment
- There were not enough events/deaths to compute a median or 95% confidence interval.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- There were not enough events/deaths to compute a median or 95% confidence interval.
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- There were not enough events/deaths to compute a median or 95% confidence interval.
- group Id
- OG002
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 8
- group Id
- OG001
- value
- 15
- group Id
- OG002
- value
- 6
- units
- Participants
- description
- Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received 8 mg/kg Ramucirumab administered as an intravenous infusion Q2W with 3 doses per 42 day cycle.
- id
- OG000
- title
- 8 mg/kg Ramucirumab (Part A)
- description
- Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.
- id
- OG001
- title
- 12 mg/kg Ramucirumab (Part A)
- description
- Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.
- id
- OG002
- title
- 12 mg/kg Ramucirumab (Part B)
- param Type
- MEDIAN
- population Description
- All randomized participants who received at least one dose of study drug.
- reporting Status
- POSTED
- time Frame
- Baseline to Date of Death from Any Cause (Up to 42 Months)
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice